AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Galapagos receives FDA RMAT designation for GLPG5101 in R/R mantle cell lymphoma.
ByAinvest
Wednesday, Aug 6, 2025 1:35 am ET1min read
Galapagos NV announced that the FDA has granted RMAT designation to GLPG5101, a CAR-T product candidate for relapsed/refractory mantle cell lymphoma. The RMAT designation aims to accelerate development and review of promising cell and gene therapies for serious or life-threatening conditions. GLPG5101 demonstrated preliminary clinical evidence of its potential to treat R/R MCL.
Galapagos NV (Euronext & NASDAQ: GLPG) has received a significant boost in its development efforts for GLPG5101, a second-generation anti-CD19/4-1BB CAR-T product candidate. The United States Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GLPG5101 for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL) [1].The RMAT designation, established under the U.S. 21st Century Cures Act, aims to expedite the development and review of promising cell and gene therapies for serious or life-threatening conditions. GLPG5101 demonstrated preliminary clinical evidence of its potential to treat R/R MCL, supporting its eligibility for the designation [1].
The clinical data from the ongoing ATALANTA-1 study, which includes a subset of patients with R/R B-cell Non-Hodgkin Lymphoma (B-NHL), including mantle cell lymphoma, played a crucial role in securing the RMAT designation. The study showed high objective and complete response rates, with a manageable safety profile [1].
The benefits of RMAT designation include increased FDA guidance, more frequent interactions during development, eligibility for accelerated approval based on surrogate or intermediate endpoints, and priority review and rolling submissions [1]. These advantages could significantly reduce the time it takes for GLPG5101 to reach patients in need.
Galapagos intends to report updated data from the ATALANTA-1 study at a future medical conference, further advancing the understanding of GLPG5101's potential [1].
References:
1. [1] https://www.globenewswire.com/news-release/2025/08/06/3128023/0/en/Galapagos-NV-Announces-U-S-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-Granted-to-GLPG5101-for-the-Treatment-of-Relapsed-Refractory-Mantle-Cell-Lymphoma.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet